India  

Bharat Biotech’s Covaxin ‘well tolerated with no serious adverse events’

Hindu Wednesday, 16 December 2020
The findings of phase 1 clinical trial of the COVID-19 vaccine have appeared on medRxiv, a preprint server.
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

CM Yediyurappa launches phase-3 trials of Covaxin in Bengaluru [Video]

CM Yediyurappa launches phase-3 trials of Covaxin in Bengaluru

Karnataka Chief Minister BS Yediyurappa virtually inaugurated phase-3 clinical trials of 'Covaxin' (COVID-19 vaccine), which is being developed by Bharat Biotech in collaboration with Indian Council of..

Credit: ANI     Duration: 02:23Published

Related news from verified sources

Covaxin induced robust immune response in Phase 1 trials: Bharat Biotech

India’s first indigenous vaccine Covaxin was successful in inducing a robust immune response without any serious adverse events during the Phase 1 trials that...
IndiaTimes Also reported by •Indian Express

COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse events

Pain at the injection site was the most common local adverse event and was well tolerated in all dose groups.
DNA